Liz Parrish

In this engaging discussion, Liz Parrish, a trailblazer in longevity science and the first patient to experiment with innovative gene therapies, shares her inspiring journey. Motivated by her son's diagnosis with type 1 diabetes, she explores the transformative potential of gene therapy for aging. Topics include the biology of telomeres, the challenges of gene therapy delivery, and ethical concerns surrounding pediatric treatments. Liz also reflects on the importance of public perception and accessibility to these groundbreaking advancements, offering insights into practical longevity habits.

Liz Parrish, Founder and CEO of BioViva Sciences, is pioneering the use of gene therapy to extend healthy lifespans. She shares her experience as the first person to undergo dual gene therapies for aging and discusses how viruses can act as effective delivery systems for genes. The conversation dives into the ethical challenges of genetic engineering, the role of mitochondria in aging, and the potential of gene therapies to replace traditional medicine. With insights on enhancing athletic performance and the future of biohacking, it's a glimpse into the cutting edge of medical science.

Daniel Ives, co-founder of Shift Bioscience, discusses groundbreaking gene therapies aimed at reversing aging and explores how reprogramming can reset cellular age. Liz Parrish, founder of BioViva, shares her experience with unapproved gene therapies and advocates for faster access for terminal patients. Medical ethicist Arthur Caplan raises concerns about the moral implications of life extension, warning that longevity treatments could exacerbate inequality. They dive into the risks, motivations, and future potential of regenerative medicine.